全文获取类型
收费全文 | 655篇 |
免费 | 77篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 53篇 |
妇产科学 | 9篇 |
基础医学 | 96篇 |
口腔科学 | 9篇 |
临床医学 | 70篇 |
内科学 | 227篇 |
皮肤病学 | 1篇 |
神经病学 | 18篇 |
特种医学 | 6篇 |
外科学 | 89篇 |
综合类 | 7篇 |
预防医学 | 27篇 |
眼科学 | 7篇 |
药学 | 34篇 |
肿瘤学 | 77篇 |
出版年
2023年 | 6篇 |
2022年 | 10篇 |
2021年 | 12篇 |
2020年 | 16篇 |
2019年 | 19篇 |
2018年 | 27篇 |
2017年 | 14篇 |
2016年 | 21篇 |
2015年 | 28篇 |
2014年 | 28篇 |
2013年 | 27篇 |
2012年 | 23篇 |
2011年 | 30篇 |
2010年 | 28篇 |
2009年 | 14篇 |
2008年 | 30篇 |
2007年 | 30篇 |
2006年 | 33篇 |
2005年 | 20篇 |
2004年 | 29篇 |
2003年 | 18篇 |
2002年 | 31篇 |
2001年 | 27篇 |
2000年 | 21篇 |
1999年 | 23篇 |
1998年 | 9篇 |
1997年 | 5篇 |
1996年 | 8篇 |
1995年 | 6篇 |
1994年 | 8篇 |
1993年 | 12篇 |
1992年 | 16篇 |
1991年 | 10篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 6篇 |
1985年 | 6篇 |
1984年 | 5篇 |
1983年 | 5篇 |
1982年 | 2篇 |
1980年 | 5篇 |
1969年 | 2篇 |
1939年 | 3篇 |
1938年 | 2篇 |
1932年 | 2篇 |
1913年 | 2篇 |
1912年 | 2篇 |
1898年 | 2篇 |
排序方式: 共有732条查询结果,搜索用时 296 毫秒
21.
Gahrton G Svensson H Cavo M Apperly J Bacigalupo A Björkstrand B Bladé J Cornelissen J de Laurenzi A Facon T Ljungman P Michallet M Niederwieser D Powles R Reiffers J Russell NH Samson D Schaefer UW Schattenberg A Tura S Verdonck LF Vernant JP Willemze R Volin L;European Group for Blood Marrow Transplantation 《British journal of haematology》2001,113(1):209-216
Out of 690 allogeneic matched sibling donor transplants for multiple myeloma reported to the European Group for Blood and Marrow Transplantation (EBMT) registry, 334 were performed during the period 1983-93 (all with bone marrow) and 356 during 1994-98 [223 with bone marrow and 133 with peripheral blood stem cells (PBSCs)]. The median overall survival was 10 months for patients transplanted during the earlier time period and 50 months for patients transplanted with hone marrow during the later period. The use of PBSCs was associated with earlier engraftment but no significant survival benefit compared to bone marrow transplants during the same time period. The improvement in survival since 1994 with the result of a significant reduction in transplant-related mortality, which was 38%, 21% and 25% at 6 months and 46%, 30% and 37% at 2 years during the earlier period, and the later period with bone marrow and PBSCs respectively. Reasons for the reduced transplant-related mortality appeared to be fewer deaths owing to bacterial and fungal infections and interstitial pneumonitis, in turn a result of earlier transplantation and less prior chemotherapy. Better supportive treatment and more frequent use of cytokines may also play a role. The improvement in survival was not directly related to the increased use of PBSCs. 相似文献
22.
23.
Per Ljungman Mark Lawler Birgitta Åsjo Gordana Bogdanovic Karin Karlsson Claes Malm Shaun R. McCann Olle Ringdén Gösta Gahrton 《British journal of haematology》1994,88(2):403-405
Summary. Human T lymphotrophic virus type 1 (HTLV-I) associated leukaemia has a poor prognosis even with chemotherapy. We describe a patient with adult T-cell leukaemia treated with allogeneic bone marrow transplantation from an HTLV-I negative identical sibling donor. During follow-up after bone marrow transplantation, HTLV-I could be repeatedly isolated inspite of anti-viral prophylaxis. The patient died of an acute encephalitis and HTLV-I could be detected in autopsy material from the brain. By a PCR-based technique using short tandem repeats (STRs) it was shown that the patient's haemopoiesis was of donor origin. This shows the infection of donor cells in vivo by an aetiological agent which has been implicated in the leukaemogenic process for adult T-cell leukaemia. 相似文献
24.
25.
26.
Anna ?gren Gustaf Edgren Malin Kardell Anders ?stlund Agneta Taune Wikman 《Trasfusione del sangue》2014,12(4):491-496
Background
Thromboelastography is increasingly used to evaluate coagulation in massively bleeding patients. The aim of this study was to investigate how different combinations of blood components affect in vitro whole blood clotting measured by thromboelastography.Materials and methods
Packed red blood cells, plasma and platelets from fresh and old blood components were mixed in vitro, in proportions of 4:4:1, 5:5:2, 8:4:1 and 2:1:0, and analysed with thromboelastography. For the ratio 4:4:1 the experiment was done at both 37 °C and 32 °C.Results
Thromboelastography curves were within normal reference values for the blood component proportions of 4:4:1 and 5:5:2. For 8:4:1, the angle and maximal amplitude were reduced below normal values, indicating low levels of fibrinogen and/or platelets. For the 2:1:0 proportion, all parameters were affected resulting in severely impaired in vitro clot formation. The reaction-time, reflecting the coagulation factor-dependent, initial clot formation, was slightly increased at a low temperature. Prolonged storage of the components did not affect the curve.Discussion
With the introduction of guidelines on the management of massive bleeding it is important to have tools for the assessment of the new protocols. In vitro evaluation of mixtures of packed red blood cells, plasma and platelets by thromboelastography may be relevant in the prediction of in vivo clot formation and haemostasis. 相似文献27.
Malik IR Chen A Brass A Ahlén G Rahman M Sällberg M Qureshi JA Frelin L 《Scandinavian journal of infectious diseases》2012,44(1):55-59
A major problem in chronic hepatitis B virus (HBV) infection is that treatment with specific antivirals is life-long since they rarely induce a sustained response. An attractive option is therefore to combine antiviral therapy with some type of immune stimulator, such as a therapeutic vaccine. Several lines of evidence suggest that a key target for the cellular immune response is the HBV core antigen (HBcAg). However, it may also be of advantage to simultaneously improve the neutralizing antibody response to the surface (S) region of HBV. We therefore generated chimeric HBcAg particles expressing preS1 residues 1-42 at the tip of the spike region. We could show that this chimeric HBcAg-preS1 protein primed both HBcAg-specific T cells and antibodies to preS1. This strongly suggests that this may be a viable approach to develop an effective bi-functional therapeutic vaccine as an add-on for the treatment of chronic HBV infections. 相似文献
28.
Schmid C Labopin M Nagler A Niederwieser D Castagna L Tabrizi R Stadler M Kuball J Cornelissen J Vorlicek J Socié G Falda M Vindeløv L Ljungman P Jackson G Kröger N Rank A Polge E Rocha V Mohty M;Acute Leukaemia Working Party of the European Group for Blood Marrow Transplantation 《Blood》2012,119(6):1599-1606
Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% ± 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT > 5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P < .001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P < .001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% ± 7%, 19% ± 4%, and 4% ± 2% at 2 years (P < .0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation. 相似文献
29.
Bumbacea D Arend SM Eyuboglu F Fishman JA Goletti D Ison MG Jones CE Kampmann B Kotton CN Lange C Ljungman P Milburn H Morris MI Muller E Mu?oz P Nellore A Rieder HL Sester U Theodoropoulos N Wagner D Sester M 《The European respiratory journal》2012,40(4):990-1013
Tuberculosis (TB) is a possible complication of solid organ and hematopoietic stem cell transplantation. The identification of candidates for preventive chemotherapy is an effective intervention to protect transplant recipients with latent infection with Mycobacterium tuberculosis from progressing to active disease. The best available proxy for diagnosing latent infection with M. tuberculosis is the identification of an adaptive immune response by the tuberculin skin test or an interferon-γ based ex vivo assay. Risk assessment in transplant recipients for the development of TB depends on, among other factors, the locally expected underlying prevalence of infection with M. tuberculosis in the target population. In areas of high prevalence, preventive chemotherapy for all transplant recipients may be justified without immunodiagnostic testing while in areas of medium and low prevalence, preventive chemotherapy should only be offered to candidates with positive M. tuberculosis-specific immune responses. The diagnosis of TB in transplant recipients can be challenging. Treatment of TB is often difficult due to substantial interactions between anti-TB drugs and immunosuppressive medications. This management guideline summarises current knowledge on the prevention, diagnosis and treatment of TB related to solid organ and hematopoietic stem cell transplantation and provides an expert consensus on questions where scientific evidence is still lacking. 相似文献
30.
M Uhlin J Gertow M Uzunel M Okas S Berglund E Watz M Brune P Ljungman M Maeurer J Mattsson 《Clinical infectious diseases》2012,55(8):1064-1073
Background.?Viral infections are major complications after allogeneic hematopoietic stem cell transplantation (HSCT). During posttransplant immunosuppression the regular T-cell control is compromised. Even if treatment strategies against infections caused by herpes viruses such as cytomegalovirus, Epstein-Barr virus, and adenovirus have improved, the mortality rate is still considerable. If primary antiviral therapy fails or cannot be tolerated, adoptive therapy with virus-specific cytotoxic T cells (CTL) can be utilized. Methods.?In this study, we used virus-specific CTLs to treat 8 patients suffering from severe viral infections after allogeneic HSCT. Using positive selection with HLA multimers and magnetic beads, we isolated CTLs from both frozen donor material as well as third-party donors within hours. Results.?At 90 days after CTL infusions 7 out of 8 patients were still living. CTLs infused from third-party donors were detected in 5 of 6 patients up to 76 days after infusion. No graft-versus-host disease associated with CTL infusions was observed. Conclusions.?Our separation approach offers a rapid alternative for adoptive CTL therapy if primary antiviral treatment strategies fail. Because no prolonged expansion steps are needed, this method may be used for early treatment of patients suffering from life-threatening infectious complications. 相似文献